Skip to content

K-Stock Briefing

https://kstockbriefing.com

  • About Us
  • News
    • News
  • IR Room
  • RESEARCH
  • Disclosures
    • Semiconductors
    • Bio & Healthcare
    • Defense
    • Shipbuilding
  • Toggle search form

[Disclosure] Hanwha Aerospace (012450) Reports Hanwha Systems’ 100%-Owned Subsidiary Hanwha Systems USA Corporation Concludes Paid-in Capital Increase, Amending Final Payment Date

Posted on December 22, 2025July 19, 2026 By K-STOCK Editor No Comments on [Disclosure] Hanwha Aerospace (012450) Reports Hanwha Systems’ 100%-Owned Subsidiary Hanwha Systems USA Corporation Concludes Paid-in Capital Increase, Amending Final Payment Date

Source Facts: Financial Supervisory Service Electronic Disclosure System (DART) / 2025-12-22

Disclosure Type: (Amendment) Decision on Paid-in Capital Increase (Major Management Matters of a Subsidiary)

💡 3-Second Summary

This disclosure confirms that Hanwha Systems USA Corporation, a subsidiary in which Hanwha Systems Co., Ltd. holds a 100% equity stake, has finalized its paid-in capital increase for securing resources to acquire stakes in other corporations, solidifying the final payment date as December 22, 2025.

📊 1. [Summary of Core Disclosure Content and Major Figures]

  • Target Original Document & Initial Filing Date: Decision on Paid-in Capital Increase (Major Management Matters of a Subsidiary) / November 24, 2025
  • Reason for Amendment: Alteration in the designated payment date
  • Key Modification (Item / Before ▷ After):
    • Payment Date: 2025-12-31 (Estimated closing date) ▷ 2025-12-22 (Definitive date upon conclusion of the capital increase)
  • Subsidiary Profile & Financial Scale (Based on End of 2024):
    • Subsidiary Name: Hanwha Systems USA Corporation (Representative: Nae-hyun Kwon / Core Business: New technology business operator)
    • Major Subsidiary Status: Non-applicable
    • Total Assets of the Subsidiary: KRW 340,299,221,430
    • Total Consolidated Assets of the Controlling Company: KRW 43,336,873,685,473 (Ratio: 0.79%)
  • Capital Structure and Allocation Method (Based on Final Confirmed Figures):
    • Type and Number of New Shares: 29,070 common shares
    • Face Value per Share: KRW 1,472
    • Total Number of Issued Shares Prior to Capital Increase: 21,603 common shares
    • Purpose of Fund Utilization: Funds for acquisition of other corporation’s securities: KRW 427,910,400,000 (Funds for facility, business acquisition, operations, debt repayment, and other purposes are none)
    • Method of Capital Increase: Shareholder allotment (Non-applicable for transfer of new share underwriting rights)
    • Issuance Price of New Shares: Confirmed issuance price: KRW 14,720,000 for common shares
    • Calculation Method for Issuance Price: Board resolution
    • Number of New Shares Allotted Per Share: 1.3456464 shares
    • Board Resolution Date (Decision Date): November 21, 2025 (Based on the board approval date of Hanwha Systems USA Corporation)
    • Securities Registration Statement Requirement: No (Not applicable for public offering, and the subsidiary is an overseas unlisted corporate entity)
  • Additional Specifications and Foreign Exchange Baseline:
    • This transaction represents a paid-in capital increase for Hanwha Systems USA Corporation, a subsidiary in which Hanwha Systems Co., Ltd. holds a 100% equity stake, and the funds will be utilized to secure resources for acquiring stakes in other corporations.
    • The face value per share, purpose of fund utilization, and issuance price of new shares were converted into KRW applying the trading standard rate of 1,472.00 KRW/USD as of November 24, 2025. The converted monetary figures remain subject to variation based on exchange rates at the actual points of capital movement.

📈 2. [Expert View: What This Disclosure Means for Investors]

This regulatory filing documents the formal finalization of a capital adjustment procedure within an international subsidiary rather than representing an immediate operational shift on Hanwha Aerospace’s standalone financial earnings. It chronicles the definitive closure of the capital procurement framework managed by the subsidiary since November 2025. According to the structural metrics registered in the text, the transaction model executes a shareholder allotment allocating KRW 427,910,400,000 against a total pool of 29,070 common shares, with the funding designated entirely for acquiring other corporation’s securities.

The primary compliance baseline is that the final payment timeline, which was previously scheduled for December 31, 2025, has been officially locked as December 22, 2025, signaling the completion of the transaction. The target entity is an overseas unlisted entity in which Hanwha Systems Co., Ltd. holds a 100% equity stake, and it registered KRW 340,299,221,430 in total assets at the end of 2024, representing a 0.79% weight against the consolidated asset total of the controlling firm. Because these adjusted metrics represent translation values derived from historical exchange rates (1,472.00 KRW/USD), investors should recognize that the localized ledger values reserve the capacity to shift depending on exchange rates at actual points of execution, focusing strictly on tracking the definitive timeline.

📝 Editor’s Comment (by K-STOCK Editor)

This announcement presents the finalized structural parameters and allocation timelines for the capital expansion framework of Hanwha Systems USA Corporation, a subsidiary in which Hanwha Systems Co., Ltd. holds a 100% equity stake. The critical variable that investors must monitor going forward is the ‘confirmed definitive closing date applied to the capital increase’ as explicitly outlined in the text.

As specified in the source filing, the current corrective disclosure establishes December 22, 2025, as the definitive date of operational closure for the paid-in capital increase, where funds are directed toward external security acquisitions. Given that the text explicitly registers that the converted volumes remain subject to exchange rate variations at the points of actual capital movement, investors should focus entirely on cross-referencing future periodic reports to verify whether the investment applications proceed according to these designated purposes and tracking the finalized parameters via regulatory channels.

📢 Disclaimer and Source Information

Source: This content has been structured and newly written based on the official data submitted to the Financial Supervisory Service Electronic Disclosure System (DART).

Investment Risk Notice: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell specific stocks. All investment decisions and financial responsibilities rest entirely with the investor.

Contact: For inquiries regarding compliance or copyright requests, please contact ksb220805@gmail.com.

Search by
Company Name or Stock Ticker.
Disclosures, Defense

Post navigation

Previous Post: [Disclosure] Hanwha Aerospace (012450) Reports Hanwha Ocean’s 100%-Owned Subsidiary Hanwha Ocean USA Holdings Corp. Concludes Paid-in Capital Increase, Amending Final Payment Date
Next Post: [Disclosure] Hanwha Aerospace (012450) Submits Corrective Disclosure to Rectify Typographical Error in Poland K9 Howitzer Contract Report

Related Posts

[Disclosure] Jeju Semiconductor (080220) to Issue $6B KRW in 8th Tranche Private CBs; Secures Zero-Coupon Financing for Core Operations Semiconductors
[Disclosure] Celltrion to List 57,364 Additional Common Shares Following Stock Option Exercise (068270) Disclosures
[Disclosure] Hana Micron (067310) Announces AGM Date for March 28; Explains Unavoidable Scheduling on ‘Concentration Day’ Semiconductors
[Disclosure] ISU PETASYS (007660) Files Reason for Holding AGM on Peak Corporate Date (March 29) to Accommodate Overseas Subsidiaries’ Audit Schedules Semiconductors
[Disclosure] Isu Petasys (007660) Hit with Pre-Notification for Unfaithful Disclosure Corporation Over Scrapped M&A and 20% Rights Offering Shift Semiconductors
[Disclosure] Celltrion (068270) Secures Final FDA Approval for Prolia & Xgeva Biosimilars ‘Stoboclo’ & ‘Osenvelt’ Disclosures

Leave a Reply Cancel reply

You must be logged in to post a comment.

  • [Disclosure] Alteogen (196170) Establishes August 6 as Record Date for Bonus Issue Share AllotmentJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Trading Suspension and Resumption Schedule for Stock Futures and OptionsJuly 16, 2026
  • [Disclosure] Alteogen (196170) Temporarily Suspends Plans for Relisting on the KOSPI MarketJuly 16, 2026
  • [Disclosure] Alteogen (196170) Announces Temporary Trading Suspension on July 16 Due to Bonus Issue DecisionJuly 16, 2026
  • [Disclosure] Alteogen (196170) Decides on Bonus Issue of 0.3 Shares per 1 Common and Preferred ShareJuly 16, 2026

Copyright © 2026 K-Stock Briefing.

Powered by PressBook Grid Dark theme